NHAS
KALV

Novo Holdings A/S’s KalVista Pharmaceuticals KALV Stock Holding History

Novo Holdings A/S’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,725,283
Closed -$18.3M – 16
2017
Q3 		$18.3M Sell
2,725,283
-176,644
-6% -$1.26M 2.39% 12
2017
Q2 		$21.4M Hold
2,901,927
– – 2.56% 13
2017
Q1 		$22.7M Hold
2,901,927
– – 2.41% 14
2016
Q4 		$20.5M Buy
+2,901,927
New +$21.4M 1.95% 13

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Novo Holdings A/S's KALV Position: Q4 2017 in Review

Novo Holdings A/S sold out of KalVista Pharmaceuticals (KALV) in Q4 2017, closing a stake of 2,725,283 shares — an estimated $18.3M sold.

Novo Holdings A/S first reported a position in KALV in Q4 2016 and held it in 4 quarters. The position peaked at $22.7M in Q1 2017. 24 funds tracked by Wall St. Rank hold KALV as of Q4 2017.

  • Novo Holdings A/S reported no remaining KalVista Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Novo Holdings A/S sold 2,725,283 KalVista Pharmaceuticals shares in Q4 2017, an estimated $18.3M.
  • Novo Holdings A/S first reported a position in KalVista Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Novo Holdings A/S's KalVista Pharmaceuticals position peaked at $22.7M in Q1 2017.
  • 24 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2017.

Based on Novo Holdings A/S's 13F filing for Q4 2017, filed 14 Feb 2018.